Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

BRCA mutation

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related biomarkers:

‹

›

BRCA mutation	HER2 Negative Breast Cancer	BRCA mutation	HER2 Negative Breast Cancer	rivoceranib + fluzoparib Sensitive: B - Late Trials rivoceranib + fluzoparib Sensitive : B	rivoceranib + fluzoparib Sensitive: B - Late Trials rivoceranib + fluzoparib Sensitive : B
BRCA mutation	Pancreatic Ductal Adenocarcinoma	BRCA mutation	Pancreatic Ductal Adenocarcinoma	PARP inhibitor Sensitive: D – Preclinical PARP inhibitor Sensitive : D	PARP inhibitor Sensitive: D – Preclinical PARP inhibitor Sensitive : D
BRCA mutation	Diffuse Large B Cell Lymphoma	BRCA mutation	Diffuse Large B Cell Lymphoma	loncastuximab tesirine-lpyl Sensitive: D – Preclinical loncastuximab tesirine-lpyl Sensitive : D	loncastuximab tesirine-lpyl Sensitive: D – Preclinical loncastuximab tesirine-lpyl Sensitive : D